December 17, 2020
A brand-new episode of AVAC’s Px Pulse podcast is ready for download. Tune in to hear the promise and complexities of long-acting injectable cabotegravir (CAB-LA)—the latest proven HIV prevention method.
Amidst a year rife with challenges, some of the best news was born out of the HIV prevention research field. This included early results from two trials—HPTN 083 and HPTN 084—showing CAB-LA was safe and highly effective at preventing HIV when compared to daily oral TDF/FTC (Truvada) in men who have sex with men, transgender women and cisgender women. Overall HIV incidence rates in the trials were remarkably low, demonstrating that both oral and injectable PrEP are safe and effective options—an especially important finding for cisgender women, for whom oral PrEP data had been inconsistent.
In this episode of Px Pulse, Raphael Landovitz and Sinead Delany-Moretlwe, lead investigators of the HPTN 083 and 084 trials, respectively, set the stage with topline research findings and discuss how CAB-LA might fit in with existing HIV prevention options. And with eyes on implementation, Definate Nhamo, a program manager from Pangaea Zimbabwe AIDS Trust (PZAT), and Jason Reed, a technical advisor with Jhpiego, outline priorities for the work ahead in policy making, programming, advocacy and funding to get CAB-LA programmed as part of a growing array of HIV prevention options.
Check out AVAC’s dedicated webpage on CAB-LA for a curated list of research and advocacy resources.